Cancer Supportive Care Products Market

Cancer Supportive Care Products Market By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Compounding Pharmacies) & Region - Forecast to 2020-2030

Market Insights on Cancer Supportive Care Products covering sales outlook, demand forecast and up-to-date key trends

Request Sample

Cancer Supportive Care Products Market Outlook & Key Findings

Cancer supportive care products market is expected to grow at about 4% y-o-y in 2020
Erythropoietin stimulating agents to hold leading revenue share, given their efficacy in treating chemotherapy-induced anemia
Sales of cancer supportive care products via hospital pharmacies to remain prominent through 2030
Usage of cancer supportive care products in treating leukemia to accelerate in the coming years
North America to spearhead the global cancer supportive care products market over the following decade

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Cancer Supportive Care Products Market Analysis

Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.

While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.

Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.

In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.

Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.

The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020-2030.

Cancer Supportive Care Products Market Trends – The Biosimilar Solution to Expensive Cancer Treatment

Biosimilar drugs (or biosimilars), used in management of several disease conditions, account for about 25% of global pharmaceutical industry.

Adoption of biosimilar drugs among patients having cancer has triggered significant advancements in cancer treatments and supportive care.

The US FDA has approved various biosimilars for treatment of cancer and supportive care management, and the figure is expected to follow a positive trend.

Further, usage of biosimilars is associated with exponential cost-savings. Recent studies stress that biosimilars will result in a reduction of US$ 54 Bn in direct expenditure on biologic drugs over 2017-2026, or around 3% of overall anticipated biologic spending within the same timeframe, ranging of US $24-150 Bn.

Prominent drivers of cost savings include number and timing of biosimilars in development and marketing, acceptability of usage among prescribers and patients, cost of biosimilar development, changes in global market size, cost-sharing, payer coverage, and other regulatory policies.

Although these figures appear promising, the expected cost savings with usage of biosimilars are projected to remain modest.

Globally, the cost of biosimilars is about 20-30% less compared to that of reference drugs. The cost savings will bank on several factors such as cost of reference drugs, their sales, and degree of competition.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Hospital Pharmacies to Remain Leading Value Creator

Among the distribution channels, hospital pharmacies are expected to generate greater total return to shareholders (TRS) – over 50% of overall cancer supportive care products market revenue.

About 33% of overall healthcare companies are looking forward to transmuting their whole business model in 2020, with hospitals, the major providers of cancer care, accounting for 66% of them.

Pharmacy is an ever-evolving landscape, as such, hospital pharmacies are striving to keep pace with surging demand for cancer supportive care products and consistent rise in healthcare expenses. With inbound costs of oncology drugs, hospital pharmacies are in a constant juggle to reduce expenses and keep the budget on track.

Hospital pharmacies are monitoring trends on cancer supportive care products that have measurable effect on pharmacy budget in order to ensure maximum savings for hospitals’ pharmaceutical expenses.

While hospital pharmacies continue to capture a bigger slice of cancer supportive care products market value, players are also unlocking new revenue lines in retail pharmacies.

Cancer Supportive Care Products Market Regional Analysis – North America Leads, APAC’s Market to Speed up

Regionally, North America continues to engage manufacturers of cancer supportive care products over the following decade. Cancer is the major cause of mortality in Canada and the second-leading cause, after cardiovascular diseases (CVD), in the US.

Around 1.9 million new incidences of cancer and 693,000 cancer mortalities were reported in Northern America in 2018.
The most prevalently diagnosed cancers are prostate and breast cancer, while lung cancer remains the leading cause of mortality in the region.

Consequently, governments in the US and Canada are substantially investing in cancer research and development of pharmaceutical drugs, especially erythropoietin stimulating agents, and granulocyte colony stimulating factors.

Moreover, the regulatory authorities have been showing immediacy in approving various cancer supportive care products. The US has granted approval to around 23 biosimilars by July 2019, of which 14 carry indications for use in oncology.

Cancer Supportive Care Products Market

In a similar vein, Asia Pacific (APAC) is also offering value-capture opportunities for players in of cancer supportive care products market.

Studies reveal that nearly half of the global cancer cases are reported in APAC, and by 2030, the number of individuals fighting cancer is likely to soar by about 35%, with mortality increasing by about 40%.

Biopharmaceutical companies in APAC are beginning to launch APAC-centric clinical therapeutics research. Within oncology domain, major portion of APAC drug development is centered on breast, lung, and colorectal cancers. Carrying an enormous cancer burden, the oncology drug market in China is expected to hit US$ 18 Bn by 2023.

Driven by expanding healthcare needs in tandem with supportive government policies. APAC represents tremendous opportunity for cancer supportive care product manufacturers. Countries are implementing steps to set up domestic environments that can leverage local talent and fetch foreign investment.

Cancer Supportive Care Products Market Players – Product Innovations and Launches to Shape Stakeholders’ Tactics

The cancer supportive care products market is witnessing the penetration of emerging players both at local and international level. The rising level of market competition is making new product launches, innovative applications, and tech-enabled developments a key priority among market players. Some of these include,

Amgen Inc. develops and delivers innovative human therapeutics – Neulasta - a PEGylated form of human granulocyte CSF.
Baxter International Inc. offers products under the business categories - Medication Delivery, Renal Care, and Pharmaceuticals. The company develops REGLAN Injection, which is a metoclopramide injection.
Bayer AG works under several business segments - Crop science, Pharmaceuticals, Animal health, and Consumer health. The company develops Xarelto, which incorporates rivaroxaban.
Daiichi Sankyo Co. Ltd. provides products under Pharmaceutical operation business unit. The company develops Naruvein Injection - a hydromorphone hydrochloride injection.
GlaxoSmithKline Plc delivers products under business segments – Vaccines, Pharmaceuticals, and Consumer healthcare. The company develops REZONIC - a neurokinin 1 receptor antagonist.

Cancer Supportive Care Products Market Future Outlook – Cannabis-based Products to Emerge as Potential Oncological Wonder

Recent medical studies are underway unleashing the potential of cannabis or cannabidiol (CBD) in cancer treatment. With limited number of opportunities for cancer treatment currently, CBD is likely to hold great promise for both patients and scientists in addressing the situation.

Given its cytotoxic, antiemetic, and anti-inflammatory effects, CBD has been garnering huge attention to its possible usage as a potent anti-cancer agent.

While regulatory bodies in the US have prohibited cannabis consumption, several states in the US, as well as some countries across the globe have legalized cannabis consumption for medical applications.

Two CBD drugs have been approved by the US Food and Drug Administration (FDA) - nabilone and dronabinol were researched as potent antiemetic medications.

Research and trials are in progress, incorporating swathes of scientists worldwide scrutinizing the potential of CBD for cancer treatment. However, these studies are yet to discover ample concrete scientific evidence to prove the safety and efficacy of CBD oil in treating cancer.

These scientific studies and research have been performed using animals or cancer cells developed in the laboratories. Human beings are more complex compared to animals, as such, results elaborated after the studies might not work as effectively for humans as they did in animal trials.

At present, the loopholes in research studies regarding consumption of CBD oil are creating hindrance for its approval as a potential medication for cancer treatment

Key Segment

Drug Class

Nonsteroidal Anti- Inflammatory Drugs
Anti-Infective
Anti-Emetics
Monoclonal Antibodies
Erythropoietin Stimulating Agents
Opioid Analgesics
Bisphosphonates
Granulocyte Colony Stimulating Factor

Indication

Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Bladder Cancer
Leukemia
Ovarian Cancer
Melanoma
Others

Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Compounding Pharmacies

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

Frequently Asked Questions

What is the Growth Outlook for Cancer Supportive Care Products Market?

The cancer supportive care products market is likely to secure a CAGR of 2.5% through 2032.

By 2032, how much can the Cancer Supportive Care Products Market Grow?

The cancer supportive care products market size is estimated to cross US$ 26.41 Bn by 2032.

What is the Current Valuation of the Cancer Supportive Care Products Market?

The cancer supportive care products market is likely to record a value of US$ 20.63 Bn in 2022.

Which Region is likely to Lead the Cancer Supportive Care Products Market?

North America is likely to lead the cancer supportive care products market.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Market Trends

3.2. Key Product/Development Trends

4. Key Success Factors

4.1. Parent Market Overview

4.2. PEST

4.3. Regulations

4.4. Key Promotional Strategies, By Key Manufacturers

5. Global Market Demand (in Volume) Analysis 2015-2019 and Forecast, 2020-2030

5.1. Historical Market Volume Analysis, 2015-2019

5.2. Current and Future Market Volume Projections, 2020-2030

5.3. Y-o-Y Growth Trend Analysis

6. Global Market - Pricing Analysis

6.1. Regional Pricing Analysis By Drug Class

6.2. Pricing Break-up

6.2.1. Manufacturer Level Pricing

6.2.2. Distributor Level Pricing

6.3. Global Average Pricing Analysis Benchmark

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2015–2019 and Forecast, 2020–2030

7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Market Background

8.1. Macro-Economic Factors

8.1.1. Global GDP Growth Outlook

8.1.2. Global Healthcare Expenditure Outlook

8.2. Forecast Factors - Relevance & Impact

8.2.1. Average Product Cost of Cancer Supportive Care Products

8.2.2. Frequency of Product Launches

8.2.3. Per Patient Spending

8.2.4. Product Awareness

8.2.5. Regulatory Approval Timeline

8.3. Value Chain

8.4. Market Dynamics

8.4.1. Drivers

8.4.2. Restraints

8.4.3. Opportunity Analysis

9. COVID19 Crisis Analysis

9.1. Current COVID19 Statistics and Probable Future Impact

9.2. Current GDP Projection and Probable Impact

9.3. Current Economic Projection as compared to 2008 Economic analysis

9.4. COVID19 and Impact Analysis

9.4.1. Revenue By Drug Class

9.4.2. Revenue By Country

9.5. 2020 Market Scenario

9.6. Quarter by Quarter Forecast

9.7. Projected recovery Quarter

9.8. Recovery Scenario – Short term, Midterm and Long Term Impact

10. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) and Volume Analysis By Drug Class , 2015 - 2019

10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Drug Class, 2020 - 2030

10.3.1. Nonsteroidal Anti- Inflammatory Drugs

10.3.2. Anti-Infective

10.3.3. Anti-Emetics

10.3.4. Monoclonal Antibodies

10.3.5. Erythropoietin Stimulating Agents

10.3.6. Opioid Analgesics

10.3.7. Bisphosphonates

10.3.8. Granulocyte Colony Stimulating Factor

10.4. Market Attractiveness Analysis By Drug Class

11. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Indication

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2019

11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 - 2030

11.3.1. Lung Cancer

11.3.2. Breast Cancer

11.3.3. Prostate Cancer

11.3.4. Liver Cancer

11.3.5. Bladder Cancer

11.3.6. Leukemia

11.3.7. Ovarian Cancer

11.3.8. Melanoma

11.3.9. Others

11.4. Market Attractiveness Analysis By Indication

12. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

12.1. Introduction / Key Findings

12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel , 2015 - 2019

12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 - 2030

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Compounding Pharmacies

12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Region

13.1. Introduction / Key Findings

13.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2019

13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030

13.3.1. North America

13.3.2. Latin America

13.3.3. Europe

13.3.4. East Asia

13.3.5. South Asia

13.3.6. Oceania

13.3.7. Middle East and Africa

13.4. Market Attractiveness Analysis By Region

14. North America Market Analysis 2015-2019 and Forecast 2020-2030

14.1. Introduction

14.2. Regional Dynamics

14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

14.4.1. By Country

14.4.1.1. U.S.

14.4.1.2. Canada

14.4.2. By Drug Class

14.4.3. By Indication

14.4.4. By Distribution Channel

14.5. Market Attractiveness Analysis

14.6. Key Market Participants - Intensity Mapping

14.7. Drivers and Restraints - Impact Analysis

15. Latin America Market Analysis 2015-2019 and Forecast 2020-2030

15.1. Introduction

15.2. Regional Dynamics

15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

15.4.1. By Country

15.4.1.1. Brazil

15.4.1.2. Mexico

15.4.1.3. Rest of Latin America

15.4.2. By Drug Class

15.4.3. By Indication

15.4.4. By Distribution Channel

15.5. Market Attractiveness Analysis

15.6. Key Market Participants - Intensity Mapping

15.7. Drivers and Restraints - Impact Analysis

16. Europe Market Analysis 2015-2019 and Forecast 2020-2030

16.1. Introduction

16.2. Regional Dynamics

16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

16.4.1. By Country

16.4.1.1. Germany

16.4.1.2. Italy

16.4.1.3. France

16.4.1.4. U.K.

16.4.1.5. Spain

16.4.1.6. Russia

16.4.1.7. Rest of Europe

16.4.2. By Drug Class

16.4.3. By Indication

16.4.4. By Distribution Channel

16.5. Market Attractiveness Analysis

16.6. Key Market Participants - Intensity Mapping

16.7. Drivers and Restraints - Impact Analysis

17. South Asia Market Analysis 2015-2019 and Forecast 2020-2030

17.1. Introduction

17.2. Regional Dynamics

17.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

17.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

17.4.1. By Country

17.4.1.1. India

17.4.1.2. Malaysia

17.4.1.3. Indonesia

17.4.1.4. Thailand

17.4.1.5. Rest of South Asia

17.4.2. By Drug Class

17.4.3. By Indication

17.4.4. By Distribution Channel

17.5. Market Attractiveness Analysis

17.6. Key Market Participants - Intensity Mapping

17.7. Drivers and Restraints - Impact Analysis

18. East Asia Market Analysis 2015-2019 and Forecast 2020-2030

18.1. Introduction

18.2. Regional Dynamics

18.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

18.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

18.4.1. By Country

18.4.1.1. China

18.4.1.2. Japan

18.4.1.3. South Korea

18.4.2. By Drug Class

18.4.3. By Indication

18.4.4. By Distribution Channel

18.5. Market Attractiveness Analysis

18.6. Key Market Participants - Intensity Mapping

18.7. Drivers and Restraints - Impact Analysis

19. Oceania Market Analysis 2015-2019 and Forecast 2020-2030

19.1. Introduction

19.2. Regional Dynamics

19.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

19.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

19.4.1. By Country

19.4.1.1. Australia

19.4.1.2. New Zealand

19.4.2. By Drug Class

19.4.3. By Indication

19.4.4. By Distribution Channel

19.5. Market Attractiveness Analysis

19.6. Key Market Participants - Intensity Mapping

19.7. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020-2030

20.1. Introduction

20.2. Regional Dynamics

20.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

20.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

20.4.1. By Country

20.4.1.1. GCC Countries

20.4.1.2. South Africa

20.4.1.3. Rest of Middle East and Africa

20.4.2. By Drug Class

20.4.3. By Indication

20.4.4. By Distribution Channel

20.5. Market Attractiveness Analysis

20.6. Key Market Participants - Intensity Mapping

20.7. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Market Analysis 2015-2019 and Forecast 2020-2030

21.1. Introduction

21.1.1. Market Value Proportion Analysis, By Key Countries

21.1.2. Global Vs. Country Growth Comparison

21.2. U.S. Market Analysis

21.2.1. By Drug Class

21.2.2. By Indication

21.2.3. By Distribution Channel

21.3. Canada Market Analysis

21.3.1. By Drug Class

21.3.2. By Indication

21.3.3. By Distribution Channel

21.4. Mexico Market Analysis

21.4.1. By Drug Class

21.4.2. By Indication

21.4.3. By Distribution Channel

21.5. Brazil Market Analysis

21.5.1. By Drug Class

21.5.2. By Indication

21.5.3. By Distribution Channel

21.6. U.K. Market Analysis

21.6.1. By Drug Class

21.6.2. By Indication

21.6.3. By Distribution Channel

21.7. Germany Market Analysis

21.7.1. By Drug Class

21.7.2. By Indication

21.7.3. By Distribution Channel

21.8. France Market Analysis

21.8.1. By Drug Class

21.8.2. By Indication

21.8.3. By Distribution Channel

21.9. Italy Market Analysis

21.9.1. By Drug Class

21.9.2. By Indication

21.9.3. By Distribution Channel

21.10. Spain Market Analysis

21.10.1. By Drug Class

21.10.2. By Indication

21.10.3. By Distribution Channel

21.11. Russia Market Analysis

21.11.1. By Drug Class

21.11.2. By Indication

21.11.3. By Distribution Channel

21.12. China Market Analysis

21.12.1. By Drug Class

21.12.2. By Indication

21.12.3. By Distribution Channel

21.13. Japan Market Analysis

21.13.1. By Drug Class

21.13.2. By Indication

21.13.3. By Distribution Channel

21.14. South Korea Market Analysis

21.14.1. By Drug Class

21.14.2. By Indication

21.14.3. By Distribution Channel

21.15. India Market Analysis

21.15.1. By Drug Class

21.15.2. By Indication

21.15.3. By Distribution Channel

21.16. Thailand Market Analysis

21.16.1. By Drug Class

21.16.2. By Indication

21.16.3. By Distribution Channel

21.17. Indonesia Market Analysis

21.17.1. By Drug Class

21.17.2. By Indication

21.17.3. By Distribution Channel

21.18. Malaysia Market Analysis

21.18.1. By Drug Class

21.18.2. By Indication

21.18.3. By Distribution Channel

21.19. Australia Market Analysis

21.19.1. By Drug Class

21.19.2. By Indication

21.19.3. By Distribution Channel

21.20. New Zealand Market Analysis

21.20.1. By Drug Class

21.20.2. By Indication

21.20.3. By Distribution Channel

21.21. GCC Countries Market Analysis

21.21.1. By Drug Class

21.21.2. By Indication

21.21.3. By Distribution Channel

21.22. South Africa Market Analysis

21.22.1. By Drug Class

21.22.2. By Indication

21.22.3. By Distribution Channel

22. Market Structure Analysis

22.1. Market Analysis by Tier of Companies (Cancer Supportive Care Products)

22.2. Market Concentration

22.3. Market Share Analysis of Top Players

22.4. Market Presence Analysis

22.4.1. By Regional Footprint of Players

22.4.2. Product Footprint by Players

22.4.3. Channel Footprint by Players

23. Competition Analysis

23.1. Competition Dashboard

23.2. Pricing Analysis by Competition

23.3. Competition Benchmarking

23.4. Competition Deep Dive

23.4.1. Amgen, Inc.

23.4.1.1. Overview

23.4.1.2. Product Portfolio

23.4.1.3. Sales Footprint

23.4.1.4. Analyst commentary

23.4.2. Johnson & Johnson Private Limited

23.4.2.1. Overview

23.4.2.2. Product Portfolio

23.4.2.3. Sales Footprint

23.4.2.4. Analyst commentary

23.4.3. Baxter

23.4.3.1. Overview

23.4.3.2. Product Portfolio

23.4.3.3. Sales Footprint

23.4.3.4. Analyst commentary

23.4.4. Merck

23.4.4.1. Overview

23.4.4.2. Product Portfolio

23.4.4.3. Sales Footprint

23.4.4.4. Analyst commentary

23.4.5. Heron Pharma

23.4.5.1. Overview

23.4.5.2. Product Portfolio

23.4.5.3. Sales Footprint

23.4.5.4. Analyst commentary

23.4.6. Tesaro

23.4.6.1. Overview

23.4.6.2. Product Portfolio

23.4.6.3. Sales Footprint

23.4.6.4. Analyst commentary

23.4.7. Enlivity Corporation

23.4.7.1. Overview

23.4.7.2. Product Portfolio

23.4.7.3. Sales Footprint

23.4.7.4. Analyst commentary

23.4.8. AmerisourceBergen Corporation (ASD Healthcare)

23.4.8.1. Overview

23.4.8.2. Product Portfolio

23.4.8.3. Sales Footprint

23.4.8.4. Analyst commentary

23.4.9. Veru, Inc.

23.4.9.1. Overview

23.4.9.2. Product Portfolio

23.4.9.3. Sales Footprint

23.4.9.4. Analyst commentary

23.4.10. ARIAD Pharmaceuticals, Inc.

23.4.10.1. Overview

23.4.10.2. Product Portfolio

23.4.10.3. Sales Footprint

23.4.10.4. Analyst commentary

23.4.11. Bendalis GmbH

23.4.11.1. Overview

23.4.11.2. Product Portfolio

23.4.11.3. Sales Footprint

23.4.11.4. Analyst commentary

23.4.12. Helsinn Healthcare

23.4.12.1. Overview

23.4.12.2. Product Portfolio

23.4.12.3. Sales Footprint

23.4.12.4. Analyst commentary

23.4.13. Novartis AG

23.4.13.1. Overview

23.4.13.2. Product Portfolio

23.4.13.3. Sales Footprint

23.4.13.4. Analyst commentary

23.4.14. Hoffmann-La Roche Ltd

23.4.14.1. Overview

23.4.14.2. Product Portfolio

23.4.14.3. Sales Footprint

23.4.14.4. Analyst commentary

23.4.15. Fagron

23.4.15.1. Overview

23.4.15.2. Product Portfolio

23.4.15.3. Sales Footprint

23.4.15.4. Analyst commentary

23.4.16. Teva Pharmaceutical Industries Ltd.

23.4.16.1. Overview

23.4.16.2. Product Portfolio

23.4.16.3. Sales Footprint

23.4.16.4. Analyst commentary

24. Assumptions and Acronyms Used

25. Research Methodology

List of Tables

Table 01: Global Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 02: Global Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 03: Global Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 04: North America Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 05: North America Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 06: North America Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 07: Latin America Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 08: Latin America Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 09: Latin America Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 10: Europe Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 11: Europe Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 12: Europe Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 13: APAC Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 14: APAC Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 15: APAC Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 16: MEA Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 17: MEA Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 18: MEA Market Value By Distribution Channel, 2020–2030(US$ Mn)

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 01: Global Oncology Drug Market Value (US$ Mn) 2020–2030

Figure 02: Global Cancer Supportive Care Drug Market – Scenario Forecast, 2020–2030(US$ Mn)

Figure 03: Global Market Value & Y-o-Y Growth (%), 2020–2030

Figure 04: Global Market Absolute $ Opportunity, 2020–2030

Figure 05: Global Market Y-o-Y Growth Comparison By Drug Classes, 2020–2030

Figure 06: Market Value Share & BPS Analysis By Drug Classes, 2020 & 2030

Figure 07: Global Market Value & Y-o-Y Growth (%) By Nonsteroidal Anti-inflammatory Drugs, 2020–2030

Figure 08: Global Market Absolute $ Opportunity By Nonsteroidal Anti-inflammatory Drugs, 2020–2030

Figure 09: Global Market Value & Y-o-Y Growth (%) By Anti-infective, 2020–2030

Figure 10: Global Market Absolute $ Opportunity By Anti-infective, 2020–2030

Figure 11: Global Market Value & Y-o-Y Growth (%) By Anti-emetics, 2020–2030

Figure 12: Global Market Absolute $ Opportunity By Anti-emetics, 2020–2030

Figure 13: Global Market Value & Y-o-Y Growth (%) Monoclonal Antibodies, 2020–2030

Figure 14: Global Market Absolute $ Opportunity By Monoclonal Antibodies, 2020–2030

Figure 15: Global Market Value & Y-o-Y Growth (%) By Erythropoietin Stimulating Agents, 2020–2030

Figure 16: Global Market Absolute $ Opportunity By Erythropoietin Stimulating Agents, 2020–2030

Figure 17: Global Market Value & Y-o-Y Growth (%) By Opioid Analgesics, 2020–2030

Figure 18: Global Market Absolute $ Opportunity By Opioid Analgesics, 2020–2030

Figure 19: Global Market Value & Y-o-Y Growth (%) By Bisphosphonates, 2020–2030

Figure 20: Global Market Absolute $ Opportunity By Bisphosphonates, 2020–2030

Figure 21: Global Market Value & Y-o-Y Growth (%) By Granulocyte Colony Stimulating Factor, 2020–2030

Figure 22: Global Market Absolute $ Opportunity By Granulocyte Colony Stimulating Factor, 2020–2030

Figure 23: Global Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 24: Global Market Attractiveness Analysis By Indication, 2020–2030

Figure 25: Global Market Y-o-Y Growth Comparison By Indication, 2020–2030

Figure 26: Market Value Share & BPS Analysis By Indication, 2020 & 2030

Figure 27: Global Market Value & Y-o-Y Growth (%) By Lung Cancer, 2020–2030

Figure 28: Global Market Absolute $ Opportunity By Lung Cancer, 2020–2030

Figure 29: Global Market Value & Y-o-Y Growth (%) By Breast Cancer, 2020–2030

Figure 30: Global Market Absolute $ Opportunity By Breast Cancer, 2020–2030

Figure 31: Global Market Value & Y-o-Y Growth (%) By Prostate Cancer, 2020–2030

Figure 32: Global Market Absolute $ Opportunity By Prostate Cancer, 2020–2030

Figure 33: Global Market Value & Y-o-Y Growth (%) By Liver Cancer, 2020–2030

Figure 34: Global Market Absolute $ Opportunity By Liver Cancer, 2020–2030

Figure 35: Global Market Value & Y-o-Y Growth (%) By Bladder Cancer, 2020–2030

Figure 36: Global Market Absolute $ Opportunity By Bladder Cancer, 2020–2030

Figure 37: Global Market Value & Y-o-Y Growth (%) By Leukemia, 2020–2030

Figure 38: Global Market Absolute $ Opportunity By Leukemia, 2020–2030

Figure 39: Global Market Value & Y-o-Y Growth (%) By Ovarian Cancer, 2020–2030

Figure 40: Global Market Absolute $ Opportunity By Ovarian Cancer, 2020–2030

Figure 41: Global Market Value & Y-o-Y Growth (%) By Melanoma, 2020–2030

Figure 42: Global Market Absolute $ Opportunity By Melanoma, 2020–2030

Figure 43: Global Market Value & Y-o-Y Growth (%) By Other Cancer, 2020–2030

Figure 44: Global Market Absolute $ Opportunity By Other Cancer 2020–2030

Figure 45: Global Market Y-o-Y Growth Comparison By Distribution Channel, 2020–2030

Figure 46: Market Value Share & BPS Analysis By Distribution Channel, 2020 & 2030

Figure 47: Global Market Value & Y-o-Y Growth (%) By Hospital Pharmacies, 2020–2030

Figure 48: Global Market Absolute $ Opportunity By Hospital Pharmacies, 2020–2030

Figure 49: Global Market Value & Y-o-Y Growth (%) By Retail Pharmacies, 2020–2030

Figure 50: Global Market Absolute $ Opportunity By Retail Pharmacies, 2020–2030

Figure 51: Global Market Value & Y-o-Y Growth (%) By Compounding Pharmacies, 2020–2030

Figure 52: Global Market Absolute $ Opportunity By Compounding Pharmacies, 2020–2030

Figure 53: Global Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 54: Market Y-o-Y Growth Comparison By Region, 2020–2030

Figure 55: Market Value Share & BPS Analysis By Region, 2020 & 2030

Figure 56: Global Market Value & Y-o-Y Growth (%) for North America Region, 2020–2030

Figure 57: Global Market Absolute $ Opportunity for North America Region, 2020–2030

Figure 58: Global Market Value & Y-o-Y Growth (%) for Latin America Region, 2020–2030

Figure 59: Global Market Absolute $ Opportunity for Latin America Region, 2020–2030

Figure 60: Global Market Value & Y-o-Y Growth (%) for Europe Region, 2020–2030

Figure 61: Global Market Absolute $ Opportunity for Europe Region, 2020–2030

Figure 62: Global Market Value & Y-o-Y Growth (%) for Asia Pacific Region, 2020–2030

Figure 63: Global Market Absolute $ Opportunity for Asia Pacific Region, 2020–2030

Figure 64: Global Market Value & Y-o-Y Growth (%) for Middle East and Africa Region, 2020–2030

Figure 65: Global Market Absolute $ Opportunity for Middle East and Africa Region, 2020–2030

Figure 66: Global Market Attractiveness Analysis By Region, 2020–2030

Figure 67: U.S. Market Value & Y-o-Y Growth (%), 2020–2030

Figure 68: U.S. Market Absolute $ Opportunity, 2020–2030

Figure 69: Canada Market Value & Y-o-Y Growth (%), 2020–2030

Figure 70: Canada Market Absolute $ Opportunity, 2020–2030

Figure 71: North America Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 72: North America Market Attractiveness Analysis By Indication, 2020–2030

Figure 73: North America Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 74: North America Market Attractiveness Analysis By Country, 2020–2030

Figure 75: Argentina Market Value & Y-o-Y Growth (%) , 2020–2030

Figure 76: Argentina Market Absolute $ Opportunity, 2020–2030

Figure 77: Brazil Market Value & Y-o-Y Growth (%), 2020–2030

Figure 78: Brazil Market Absolute $ Opportunity, 2020–2030

Figure 79: Mexico Market Value & Y-o-Y Growth (%), 2020–2030

Figure 80: Mexico Market Absolute $ Opportunity, 2020–2030

Figure 81: Rest Of Latin America Market Value & Y-o-Y Growth (%), 2020–2030

Figure 82: Rest Of Latin America Market Absolute $ Opportunity, 2020–2030

Figure 83: Latin America Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 84: Latin America Market Attractiveness Analysis By Indication, 2020–2030

Figure 85: Latin America Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 86: Latin America Market Attractiveness Analysis By Country, 2020–2030

Figure 87: Germany Market Value & Y-o-Y Growth (%) , 2020–2030

Figure 88: Germany Market Absolute $ Opportunity, 2020–2030

Figure 89: U.K. Market Value & Y-o-Y Growth (%), 2020–2030

Figure 90: U.K. Market Absolute $ Opportunity, 2020–2030

Figure 91: France Market Value & Y-o-Y Growth (%), 2020–2030

Figure 92: France Market Absolute $ Opportunity, 2020–2030

Figure 93: Italy Market Value & Y-o-Y Growth (%), 2020–2030

Figure 94: Italy  Market Absolute $ Opportunity, 2020–2030

Figure 95: Spain Market Value & Y-o-Y Growth (%), 2020–2030

Figure 96: Spain Market Absolute $ Opportunity, 2020–2030

Figure 97: Nordic Market Value & Y-o-Y Growth (%), 2020–2030

Figure 98: Nordic Market Absolute $ Opportunity, 2020–2030

Figure 99: Russia Market Value & Y-o-Y Growth (%), 2020–2030

Figure 100: Russia Market Absolute $ Opportunity, 2020–2030

Figure 101: Rest Of Europe Market Value & Y-o-Y Growth (%), 2020–2030

Figure 102:  Rest Of Europe Market Absolute $ Opportunity, 2020–2030

Figure 103: Europe Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 104: Europe Market Attractiveness Analysis By Indication, 2020–2030

Figure 105: Europe Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 106: Europe Market Attractiveness Analysis By Country, 2020–2030

Figure 107: Greater China Market Value & Y-o-Y Growth (%), 2020–2030

Figure 108: Greater China Market Absolute $ Opportunity, 2020–2030

Figure 109: India Market Value & Y-o-Y Growth (%), 2020–2030

Figure 110: India Market Absolute $ Opportunity, 2020–2030

Figure 111: Japan Market Value & Y-o-Y Growth (%), 2020–2030

Figure 112: Japan Market Absolute $ Opportunity, 2020–2030

Figure 113: Australia and New Zealand Market Value & Y-o-Y Growth (%), 2020–2030

Figure 114: Australia and New Zealand Market Absolute $ Opportunity, 2020–2030

Figure 115: Rest of APAC Market Value & Y-o-Y Growth (%), 2020–2030

Figure 116: Rest of APAC Market Absolute $ Opportunity, 2020–2030

Figure 117: APAC Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 118: APAC Market Attractiveness Analysis By Indication, 2020–2030

Figure 119: APAC Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 120: APAC Market Attractiveness Analysis By Country, 2020–2030

Figure 121: GCC Market Value & Y-o-Y Growth (%), 2020–2030

Figure 122: GCC America Market Absolute $ Opportunity, 2020–2030

Figure 123: South Africa Market Value & Y-o-Y Growth (%), 2020–2030

Figure 124: South Africa Market Absolute $ Opportunity, 2020–2030

Figure 125: Rest Of MEA Market Value & Y-o-Y Growth (%), 2020–2030

Figure 126: Rest Of MEA Market Absolute $ Opportunity, 2020–2030

Figure 127: MEA Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 128: MEA Market Attractiveness Analysis By Indication, 2020–2030

Figure 129: MEA Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 130: MEA Market Attractiveness Analysis By Country, 2020–2030